MDT stellt den TMR1370 vor - einen magnetischen Schalter-IC mit extrem niedrigem Stromverbrauch, der mehr als zwei Jahre Standby-Betrieb in CGM-Geräten ermöglicht

This reads as a component-level spec upgrade, not a market-moving product cycle. The economic value is likely to accrue upstream to CGM OEMs only if lower standby draw materially improves device reliability, form factor, or replacement intervals; otherwise the monetization is mostly design-win defense for MDT rather than incremental revenue expansion. In other words, the headline is more about qualification leverage in a niche socket than about near-term P&L.

The second-order winner set is broader than MDT: CGM brands such as DXCM and ABT benefit if a smaller power budget reduces user friction, but the effect should show up first in lower return rates and better retention, not in a step-change in unit growth. Competitively, this raises the bar for alternative magnetic switch vendors (Allegro, Infineon, TI-adjacent sensor offerings) because ultra-low standby power is becoming a baseline requirement in wearables; however, switching costs in medical design-ins are high, so incumbency matters more than specs.

Risk/reversal is mostly about qualification, not technology. If the part is not already in late-stage OEM validation, the time horizon is 6-18 months and the claim remains promotional; if it is qualified, the near-term catalyst is design-in announcements and distributor stocking, not unit revenue. The contrarian view is that the market will overpay for the nA headline while underweighting supply consistency, yield, and medical-device regulatory validation, which are the real constraints on content expansion.